These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35788237)

  • 21. The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.
    Liu B; Bai M; Wang Y; Wang D; Zhao J; Li L; Dong R; Sun S
    Eur J Intern Med; 2019 Nov; 69():32-41. PubMed ID: 31447275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
    Lecumberri R; Krsnik I; Askari E; Sirvent M; González-Pérez MS; Escalante F; Pradillo V; Tamariz LE; Cánovas V; Alegre A; Gironella M; González-García ME; Infante MS; Lakhwani S; Martínez-Bilbao C; Dourdil V; Ramírez-Payer Á; Sarrá J; Cibeira MT
    Amyloid; 2020 Sep; 27(3):163-167. PubMed ID: 32106714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.
    Hassan H; Anwer F; Javaid A; Hashmi H
    Crit Rev Oncol Hematol; 2021 Sep; 165():103435. PubMed ID: 34343658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
    Minnema MC; Dispenzieri A; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Grogan M; Witteles R; Ruberg FL; Maurer MS; Tran N; Qin X; Vasey SY; Weiss BM; Vermeulen J; Jaccard A
    JACC CardioOncol; 2022 Nov; 4(4):474-487. PubMed ID: 36444227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
    San-Miguel J; Usmani SZ; Mateos MV; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
    Haematologica; 2021 Jun; 106(6):1725-1732. PubMed ID: 32354874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
    Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
    Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
    Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
    Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
    Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral versus intravenous fluoropyrimidines for colorectal cancer.
    Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
    Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
    Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
    Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
    Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
    [No Abstract]   [Full Text] [Related]  

  • 33. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
    Luo MM; Usmani SZ; Mateos MV; Nahi H; Chari A; San-Miguel J; Touzeau C; Suzuki K; Kaiser M; Carson R; Heuck C; Qi M; Zhou H; Sun YN; Parasrampuria DA
    J Clin Pharmacol; 2021 May; 61(5):614-627. PubMed ID: 33145788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
    Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
    Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting.
    Tam AH; Jung Y; Young R; Huang CY; Wolf J; Shah N; Wong SW; Martin TG; Lo M
    J Oncol Pharm Pract; 2022 Dec; 28(8):1819-1825. PubMed ID: 34647506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
    Usmani SZ; Mateos MV; Hungria V; Iida S; Bahlis NJ; Nahi H; Magen H; Cavo M; Hulin C; White D; De Stefano V; Fastenau J; Slavcev M; Heuck C; Qin X; Pei H; Masterson T; Lantz K; Gries KS
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):619-631. PubMed ID: 32852632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
    Suzuki K; Wechalekar AD; Kim K; Shimazaki C; Kim JS; Ikezoe T; Min CK; Zhou F; Cai Z; Chen X; Iida S; Katoh N; Fujisaki T; Shin HJ; Tran N; Qin X; Vasey SY; Tromp B; Weiss BM; Comenzo RL; Kastritis E; Lu J
    Ann Hematol; 2023 Apr; 102(4):863-876. PubMed ID: 36862168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
    Slavcev M; Spinelli A; Absalon E; Masterson T; Heuck C; Lam A; De Cock E
    Clinicoecon Outcomes Res; 2021; 13():465-473. PubMed ID: 34135605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
    Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
    Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.